Lenalidomide - CAS 191732-72-6

Catalog Number Size Price Stock Quantity
BP-900061 25 g $298 In stock
Add to cart

Cereblon binder; induces ubiquitination and degradation of CK1a and transcription factors IKZF1, IKZF3 and SALL4 by E3 ubiquitin ligase

* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.

Molecular Formula
Molecular Weight


    • Specification
      • Purity
        ≥98% (HPLC)
        White solid powder
        Shelf Life
        >2 years if stored properly
        Store at -20°C
        Room temperature in continental US; may vary elsewhere.
        CC5013; CC-5013; CC 5013; IMiD1; Lenalidomide; US brand name: Revlimid
    • Properties
      • Melting Point
        >250°C (dec.)
        Chemical Name
        InChI Key
        Canonical SMILES
        Biological Activity
        Thalidomide analog. Immune modulatory drug and cereblon binding compound. Induces ubiquitination and degradation of casein kinase (CK) 1α by the E3 ubiquitin ligase CRL4CRBN. Also TNF-α inhibitor and angiogenesis inhibitor. Promotes degradation of transcription factor SALL4.
    • Reference Reading
      • 1.Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
        Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Vel N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282.
        BACKGROUND: Ixazomib is an oral proteasome inhibitor that is currently being studied for the treatment of multiple myeloma.
        2.A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome.
        Cherian MA1, Tibes R2, Gao F3, Fletcher T1, Fiala M1, Uy GL1, Westervelt P1, Jacoby MA1, Cashen AF1, Stockerl-Goldstein K1, DiPersio JF1, Vij R1. Leuk Lymphoma. 2016 Apr 27:1-6. [Epub ahead of print]
        Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by bone marrow failure which frequently progress to acute myeloid leukemia. Patients who fail to respond to, or progress on first-line DNA hypomethylating agents (HMA) have a poor prognosis. Conventionally dosed lenalidomide has activity in 5q-MDS. In other subtypes, it may reduce RBC transfusion requirements but does not result in cytogenetic responses. We previously reported that high-dose lenalidomide induction (50 mg/day) results in complete remissions in a high fraction of patients. We, therefore, conducted a Phase 2 trial of the same regimen in MDS refractory to HMA. Marrow complete remissions were seen in 33% of patients and hematological improvement in 8% of patients. Significant infections complicated more than 50% of cases. Future trials to explore alternative dosing schedules of high-dose lenalidomide to increase efficacy while decreasing toxicity are warranted.
Bio Calculators
Stock concentration: *
Desired final volume: *
Desired concentration: *


* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
Related Products
BOC Sciences Support

Please contact us with any specific requirements and we will get back to you as soon as possible.

  • Verification code

We invite you to contact us at or through our contact form above for more information about our services and products.

  • International:
  • US & Canada (Toll free):
  • Email:
  • Fax:
  • Email:
Inquiry Basket